Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) – Small Entity Compliance Guide
Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) – Small Entity Compliance Guide guidance in accordance with section 212 of the…
Read more →Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial
Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial guidance is to provide recommendations to sponsors interested in studying…
Read more →Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies
Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies…
Read more →Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe Guidance for Industry
Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe Guidance for Industry guidance is intended to assist applicants of abbreviated…
Read more →Definitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act Guidance for Industry
Definitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act Guidance for Industry this document given by…
Read more →Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products
Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products guidance describes FDA’s current recommendations regarding adjusting for covariates in the statistical…
Read more →